with larger ranges of innovation (topical lotions and tablets) within the pipeline for PsO.
Newer Treatment for PsO
“There will always be a place for injectable biologics in the PsO treatment toolbox, especially in severe patients. However, the recent and future releases of biosimilars will sap the profits of anyone with an expired patent, and essentially open the floodgates of innovation in the field,” says Tiffany Chan, an Immunology Analyst at GlobalData.
This paves approach for newer alternative for producers in direction of the focused and various therapies for PsO sufferers.
Among the main group of firms concerned within the change are:
First group:
- Belgium-based UCB
- Swedish firm Affibody
- German’s Merck
Second group:
- US-based Bristol-Myers Squibb
- India’s Dr. Reddy’s Laboratory
- Israel’s Can-Fite Biopharma
Third group:
- US-based firms Arcutis and Dermavant
“The lack of treatments for patients at either extremity of the disease spectrum gives scope for new entrants to significantly grow the market. By attempting to fulfill specific unmet needs, pharmaceutical companies could generate new treatment options for patients that could reduce the need for administration and monitoring by healthcare professionals,” says Chan.
Source: Medindia
